{"id":10111,"date":"2021-06-01T11:18:43","date_gmt":"2021-06-01T18:18:43","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10111"},"modified":"2021-06-03T11:19:23","modified_gmt":"2021-06-03T18:19:23","slug":"colchicine-for-community-treated-patients-with-covid-19-colcorona-a-phase-3-randomised-double-blinded-adaptive-placebo-controlled-multicentre-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/01\/colchicine-for-community-treated-patients-with-covid-19-colcorona-a-phase-3-randomised-double-blinded-adaptive-placebo-controlled-multicentre-trial\/","title":{"rendered":"Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The anti-inflammatory drug colchicine did not change the rate of hospital admission or death related to COVID-19 (a composite endpoint) in a phase 3 double-blind placebo-controlled trial among non-hospitalized patients diagnosed with COVID-19 either by PCR testing or clinical criteria (OR=0.79, 95%CI: 0.61-1.03). The primary endpoint occurred in 4.7% (104 of 2,235) patients in the colchicine group and in 5.8% (131 of 2,253) of patients in the placebo group. Among those with PCR-confirmed COVID-19 (n=4,159), the primary endpoint occurred in 4.6% in the colchicine group vs 6.0% in the placebo group (OR=0.75, 95%CI: 0.57-0.99). Pneumonia occurred in fewer patients in the colchicine group (2.9% vs 4.1%), but diarrhea was reported in more patients in the colchicine group (13.7% vs 7.3%). Serious adverse events were similar in both groups.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Tardif et al.\u00a0(May 2021). Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial. The Lancet Respiratory Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S2213-2600(21)00222-8\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S2213-2600(21)00222-8<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The anti-inflammatory drug colchicine did not change the rate of hospital admission or death related to COVID-19 (a composite endpoint) in a phase 3 double-blind placebo-controlled trial among non-hospitalized patients diagnosed with COVID-19 either by PCR testing or clinical criteria (OR=0.79, 95%CI: 0.61-1.03). The primary endpoint occurred in 4.7% (104 of 2,235) patients in the&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/01\/colchicine-for-community-treated-patients-with-covid-19-colcorona-a-phase-3-randomised-double-blinded-adaptive-placebo-controlled-multicentre-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-10111","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10111"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10111\/revisions"}],"predecessor-version":[{"id":10112,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10111\/revisions\/10112"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10111"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}